ELISA for detection of humoral immunity against measles by Zahoor, Muhammad Asif et al.
EXCLI Journal 2015;14:1133-1134 – ISSN 1611-2156 
Received: October 01, 2015, accepted: October 18, 2015, published: October 20, 2015 
 
 
1133 
Letter to the editor: 
ELISA FOR DETECTION OF HUMORAL IMMUNITY AGAINST 
MEASLES 
 
Muhammad Asif Zahoor*, Muhammad Saqalein, Zeeshan Nawaz 
 
Department of Microbiology, Govt. College University, Faisalabad-Pakistan 
 
* Corresponding author: Muhammad Asif Zahoor, Department of Microbiology,  
Govt. College University, Faisalabad-Pakistan; Tel: 92-41-9201205;  
E-mail: drasifzahoor@gcuf.edu.pk 
 
http://dx.doi.org/10.17179/excli2015-607 
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/). 
 
Dear Editor, 
 
Measles is a highly infectious and contagious disease of the respiratory system caused by 
Morbilivirus (Hashiguchi et al., 2011). The clinical disease has been characterized by high fe-
ver, cough, conjunctivitis, coryza, malaise, maculopapular rash and erythematous patches 
throughout the body along with increased mortality among non-vaccinated children (Ellison, 
1931; Fazlalipour et al., 2008). Expanded Program on Immunization (EPI) has been launched 
in 1974 under the umbrella of World Health Organization (WHO) with the ultimate objective 
of elimination of Vaccine Preventable Diseases (VPDs) in children, further this program was 
initiated in Pakistan during 1978 (Ali, 2000; Bugvi et al., 2014).  Among the VPDs, measles 
has been considered as one of most important diseases in children throughout the world par-
ticularly in developing countries (Rabenau et al., 2007; Liu et al., 2013). Furthermore, vac-
cination against measles is widespread which significantly reduces the mortality and morbidi-
ty across the globe (Perry and Halsey, 2004; Leuridan and Van Damme, 2007). Vaccination 
with first dose is recommended at the age of 9 months with booster dose at the age of 12 or 15 
months  with either live attenuated measles virus or Measles-Mumps-Rubella complex 
(MMR) as described (Leuridan and Van Damme, 2007; Sheikh et al., 2011). The immuniza-
tion against measles virus usually resulted in protection due to humoral as well as cell mediat-
ed immune response (Ovsyannikova et al., 2003). Many immunodiagnostic methods have 
been used for the detection of anti-measles antibodies as described by Perry and Halsey 
(2004). Among those, Enzyme Linked Immunosorbent Assay (ELISA) has been reported as 
more sensitive and specific with reproducibility of results for detection of anti-measles anti-
bodies (Fazlalipour et al., 2008). Further, ELISA for measles has been reported to detect and 
quantify anti-measles IgG antibodies with high sensitivity and specificity (Rabenau et al., 
2007).  
Therefore, keeping in view the importance and significance of measles, this preliminary 
study was designed to develop an ELISA for detection of humoral immunity. For this purpose 
ELISA plates were coated with measles virus CAM-70 strain (PT Bio Farma, Bandung, Indo-
nesia) which contain not less than 1000 CCID50 in 0.5 ml. Coating of plates was performed 
using carbonate buffer as described by van der Werff (2008). Briefly, 100 µl of virus diluted 
with 0.05 M carbonate buffer was added in wells of ELISA plates in duplicate, following 
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overnight incubation at 4 °C, blocking was achieved by adding 300 µl of blocking buffer 
(PBS + 10 % w/v skimmed milk powder). ELISA was performed as recently described by 
Zahoor et al. (2015). Briefly, each serum sample was diluted with serum diluent and 100 µL 
of each diluted serum sample was added in each well of ELISA plate along with controls 
(Nova Tec Immunodiagnostica GmbH, Germany). Following incubation of ELISA plate for 
one hour at 37 °C, plate was washed with 300 µl of washing buffer. In the next step, 100 µl 
measles anti-IgG conjugate (Nova Tec Immunodiagnostica GmbH, Germany) was added into 
all wells except for the blank well, and kept for 30 minutes at room temperature. Finally, 
100 µl tetramethylbenzidine substrate (TMB) was added into all wells, and kept at room tem-
perature for 15 minutes in dark. Reaction was stopped by using 100 µl of stop solution into all 
wells. Absorbance of the ELISA plate was determined at 450 nm within 30 minutes after ad-
dition of the stop solution (Biotek®, ELX 808, USA). Altogether, it was concluded that the 
developed ELISA may be used to detect humoral immunity from vaccinated children to eval-
uate the effectiveness of measles vaccination following further standardization and optimiza-
tion of developed ELISA protocol.  
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